TABLE 1.
List of approved CAR‐T therapies in the United States
| Approved CAR‐T brand name (generic name) | Approved indication(s) | Target | Year of first US approval |
|---|---|---|---|
| CARVYKTI (ciltacabtagene autoleucel) | Adult R/R multiple myeloma | BCMA | 2022 |
| ABCEMA (idecabtagene vicleucel) | Adult R/R multiple myeloma | BCMA | 2021 |
| BREYANZI (lisocabtagene maraleucel) | Adult R/R large B‐cell lymphoma | CD19 | 2021 |
| TECARTUS (brexucabtagene autoleucel) | Adult R/R mantle cell lymphoma; adult R/R B‐cell precursor acute lymphoblastic leukemia | CD19 | 2020 |
| YESCARTA (axicabtagene ciloleucel) | Adult R/R large B‐cell lymphoma; adult R/R follicular lymphoma | CD19 | 2017 |
| KYMRIAH (tisagenlecleucel) | Adult R/R large B‐cell lymphoma; pediatric refractory acute lymphoblastic leukemia | CD19 | 2017 |
Abbreviations: BCMA, B‐cell maturation antigen; CD19, cluster of differentiation 19; R/R, relapsed or refractory.